- Investing Ideas
- U.S. Pharmaceuticals & Biotech Sustainable Track Record
U.S. Pharmaceuticals & Biotech Sustainable Track Record
Results
13
Companies which have reinvested earnings to sustain 10% yearly growth over 5 years.
13 companies
CorMedix
Market Cap: US$592.3m
A biopharmaceutical company, focuses on developing and commercializing therapeutic products for life-threatening diseases and conditions in the United States.
CRMD
US$7.52
7D
2.3%
1Y
-37.6%
Incyte
Market Cap: US$24.0b
A biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan.
INCY
US$120.60
7D
-7.2%
1Y
55.2%
Protalix BioTherapeutics
Market Cap: US$186.9m
A biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system.
PLX
US$2.37
7D
1.7%
1Y
66.9%
TG Therapeutics
Market Cap: US$6.9b
A commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally.
TGTX
US$48.74
7D
-8.9%
1Y
75.9%
CareDx
Market Cap: US$2.5b
Provides solutions for improving outcomes for transplant patients and advancing organ health in the United States and internationally.
CDNA
US$47.09
7D
31.7%
1Y
266.5%
Aurinia Pharmaceuticals
Market Cap: US$1.9b
A biopharmaceutical company, engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs in the United States and Japan.
AUPH
US$14.93
7D
-0.2%
1Y
27.6%
Rigel Pharmaceuticals
Market Cap: US$717.5m
A biotechnology company, develops and provides therapies that enhance the lives of patients with hematologic disorders and cancer in the United States.
RIGL
US$38.70
7D
-0.9%
1Y
29.8%
Exelixis
Market Cap: US$13.8b
An oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States.
EXEL
US$56.00
7D
-0.9%
1Y
49.5%
Medpace Holdings
Market Cap: US$16.1b
Provides clinical research-based drug and medical device development services in North America, Europe, Asia, South America, Africa, and Australia.
MEDP
US$575.08
7D
-1.7%
1Y
33.6%
Eli Lilly
Market Cap: US$1.0t
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally.
LLY
US$1,115.68
7D
-8.6%
1Y
45.7%
Earth Science Tech
Market Cap: US$28.7m
Together with its subsidies, focuses on health and wellness industry.
ETST
US$0.092
7D
-16.3%
1Y
-50.1%
CapForce
Market Cap: US$96.3m
A precision medicine company, develops and commercializes molecular microbiology solutions for life threatening infectious diseases in the United States and internationally.
CFOR
US$6.80
7D
-62.2%
1Y
17,202.8%
ACADIA Pharmaceuticals
Market Cap: US$4.6b
A biopharmaceutical company, focuses on the development and commercialization of medicines for neurological and rare disease in North America.
ACAD
US$27.15
7D
3.1%
1Y
14.1%